Picture of RIZAP logo

2928 — RIZAP News Story

0.000.00%
jp flag iconLast trade - 00:00
Consumer DefensivesSpeculativeMid CapNeutral

2022/23 group results (IFRS)

May 15 (Reuters)- 
              Rizap Group, Inc. 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                   Year ended      Year ended        Year to         NEXT  
                Mar 31, 2023    Mar 31, 2022    Mar 31, 2024       YEAR    
                   LATEST         YEAR-AGO         COMPANY       COMPANY   
                   RESULTS         RESULT         FORECAST     H1 FORECAST 
  Sales            160.52          160.96          180.00                  
                 (-0.3 pct)      (-4.5 pct)      (+12.1 pct)               
  Operating       loss 4.51          5.82         loss 4.50                
                                (+264.8 pct)                               
  Pretax          loss 6.64          4.19         loss 6.20                
  Net            loss 12.73          2.13         loss 9.00                
                                 (+32.5 pct)                               
  EPS Basic    loss 22.89 yen     3.83 yen     loss 16.18 yen              
  EPS Diluted  loss 22.89 yen     3.83 yen                                 
  Ann Div            NIL             NIL             NIL                   
  -Q2 Div            NIL             NIL             NIL                   
  -Q4 Div            NIL             NIL             NIL                   
 
  NOTE - Rizap Group, Inc.. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company.
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=2928.SP

Recent news on RIZAP

See all news